<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04244201</url>
  </required_header>
  <id_info>
    <org_study_id>VAPOROX-VHT100-01</org_study_id>
    <nct_id>NCT04244201</nct_id>
  </id_info>
  <brief_title>Vaporous Hyperoxia Therapy (VHT) in the Treatment of Foot Wounds</brief_title>
  <acronym>VHT1</acronym>
  <official_title>Evaluation of Vaporous Hyperoxia Therapy (VHT) for Chronic Wounds</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vaporox</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vaporox</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effectiveness of Vaporous Hyperoxia Therapy
      (VHT), previously named Misty (WTS-1000) for the treatment of chronic foot ulcers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The Vaporox VHT1 study is a single arm study evaluating the efficacy of Vaporous Hyperoxia
      Therapy (VHT), previously named Misty (WTS-1000), as an adjunctive therapy for the treatment
      of chronic foot ulcers.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 6, 2005</start_date>
  <completion_date type="Actual">October 4, 2007</completion_date>
  <primary_completion_date type="Actual">March 1, 2007</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound healing rate at 12 weeks</measure>
    <time_frame>12 weeks</time_frame>
    <description>The percent of subjects that achieved wound healing at 12 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to wound healing</measure>
    <time_frame>up to 12 weeks</time_frame>
    <description>Time to achieve complete wound healing</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">31</enrollment>
  <condition>Neuropathic Foot Ulcer</condition>
  <condition>Foot Ulcer</condition>
  <arm_group>
    <arm_group_label>VHT treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will be treated with VHT for 1 hour four times per week</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Vaporous Hyperoxia Therapy</intervention_name>
    <description>1 hour of treatment, 4 times per week</description>
    <arm_group_label>VHT treatment</arm_group_label>
    <other_name>VHT</other_name>
    <other_name>Misty</other_name>
    <other_name>WTS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diabetic, arterial, and venous foot ulcers as well as decubitus ulcers

          -  University of Texas Health Science Center classification: Grade 0, 1, and 2

        Exclusion Criteria:

          -  Ulcers above the medial and lateral malleoli

          -  Etiology of cancer/neoplastic

          -  Etiology of collagen vascular disease

          -  Etiology of gangrene

          -  Etiology of osteomyelitis (Grade 3)

          -  Etiology of thermal burns

          -  Etiology of radiation injury

          -  Pregnancy

          -  Acute skin conditions

          -  Inadequate perfusion to support treatment

          -  Wounds where the end cannot be probed

          -  Wounds covered with petroleum based dressing

          -  Non-compliant patients
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clifford J Wolf, DPM</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolf Podiatry</affiliation>
  </overall_official>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 23, 2020</study_first_submitted>
  <study_first_submitted_qc>January 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 28, 2020</study_first_posted>
  <last_update_submitted>January 28, 2020</last_update_submitted>
  <last_update_submitted_qc>January 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>diabetic foot</keyword>
  <keyword>leg ulcer</keyword>
  <keyword>skin ulcer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Foot Ulcer</mesh_term>
    <mesh_term>Ulcer</mesh_term>
    <mesh_term>Hyperoxia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

